97 related articles for article (PubMed ID: 26204487)
1. Down-regulation of α-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface.
Cheng TC; Tu SH; Chen LC; Chen MY; Chen WY; Lin YK; Ho CT; Lin SY; Wu CH; Ho YS
Oncotarget; 2015 Aug; 6(25):21283-300. PubMed ID: 26204487
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.
de Heer EC; Zois CE; Bridges E; van der Vegt B; Sheldon H; Veldman WA; Zwager MC; van der Sluis T; Haider S; Morita T; Baba O; Schröder CP; de Jong S; Harris AL; Jalving M
J Exp Clin Cancer Res; 2023 Jun; 42(1):143. PubMed ID: 37280675
[TBL] [Abstract][Full Text] [Related]
4. Divergent Chemoenzymatic Synthesis of Asymmetrical-Core-Fucosylated and Core-Unmodified N-Glycans.
Li T; Huang M; Liu L; Wang S; Moremen KW; Boons GJ
Chemistry; 2016 Dec; 22(52):18742-18746. PubMed ID: 27798819
[TBL] [Abstract][Full Text] [Related]
5. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Timmerman LA; Holton T; Yuneva M; Louie RJ; Padró M; Daemen A; Hu M; Chan DA; Ethier SP; van 't Veer LJ; Polyak K; McCormick F; Gray JW
Cancer Cell; 2013 Oct; 24(4):450-65. PubMed ID: 24094812
[TBL] [Abstract][Full Text] [Related]
6. The emerging importance of α-L-fucose in human breast cancer: a review.
Listinsky JJ; Siegal GP; Listinsky CM
Am J Transl Res; 2011 Aug; 3(4):292-322. PubMed ID: 21904652
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents.
Krushkal J; Zhao Y; Hose C; Monks A; Doroshow JH; Simon R
Cancer Inform; 2017; 16():1176935117747259. PubMed ID: 29276373
[TBL] [Abstract][Full Text] [Related]
8. The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
Jiang X; Wang Y; Guo L; Wang Y; Miao T; Ma L; Wei Q; Lin X; Mao JH; Zhang P
Breast Cancer Res; 2024 Mar; 26(1):37. PubMed ID: 38454442
[TBL] [Abstract][Full Text] [Related]
9. Genetics of enzymatic dysfunctions in metabolic disorders and cancer.
Mahé M; Rios-Fuller TJ; Karolin A; Schneider RJ
Front Oncol; 2023; 13():1230934. PubMed ID: 37601653
[TBL] [Abstract][Full Text] [Related]
10. Induced-volatolomics for the design of tumour activated therapy.
Châtre R; Blochouse E; Eid R; Djago F; Lange J; Tarighi M; Renoux B; Sobilo J; Le Pape A; Clarhaut J; Geffroy C; Opalinski I; Tuo W; Papot S; Poinot P
Chem Sci; 2023 May; 14(18):4697-4703. PubMed ID: 37181780
[TBL] [Abstract][Full Text] [Related]
11. USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer.
Xiao Y; Jiang X; Yin K; Miao T; Lu H; Wang W; Ma L; Zhao Y; Liu C; Qiao Y; Zhang P
Oncogenesis; 2023 Mar; 12(1):12. PubMed ID: 36864055
[TBL] [Abstract][Full Text] [Related]
12. Dual role of fucosidase in cancers and its clinical potential.
Fu J; Guo Q; Feng Y; Cheng P; Wu A
J Cancer; 2022; 13(10):3121-3132. PubMed ID: 36046653
[TBL] [Abstract][Full Text] [Related]
13. Association and prognostic significance of alpha-L-fucosidase-1 and matrix metalloproteinase 9 expression in esophageal squamous cell carcinoma.
Yu XY; Lin SC; Zhang MQ; Guo XT; Ma K; Wang LX; Huang WT; Wang Z; Yu X; Wang CG; Zhang LJ; Yu ZT
World J Gastrointest Oncol; 2022 Feb; 14(2):498-510. PubMed ID: 35317318
[TBL] [Abstract][Full Text] [Related]
14. Detection of Bacterial α-l-Fucosidases with an
Luijkx YMCA; Henselijn AJ; Bosman GP; Cramer DAT; Giesbers KCAP; van 't Veld EM; Boons GJ; Heck AJR; Reiding KR; Strijbis K; Wennekes T
Molecules; 2022 Feb; 27(5):. PubMed ID: 35268716
[TBL] [Abstract][Full Text] [Related]
15. Altered mRNA Expression of Fucosyltransferases and Fucosidase Predicts Prognosis in Human Oral Carcinoma.
Mehta K; Patel K; Pandya S; Patel P
Int J Mol Cell Med; 2021; 10(2):123-131. PubMed ID: 34703796
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Evaluation of a Radiolabeled PET (Positron Emission Tomography) Probe for Visualization of In Vivo α-Fucosidase Expression.
Cotton J; Goehring CM; Kuehn A; Maurer A; Fuchs K; Pichler BJ
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451843
[TBL] [Abstract][Full Text] [Related]
17. Rapid and Accurate Visualization of Breast Tumors with a Fluorescent Probe Targeting α-Mannosidase 2C1.
Fujita K; Kamiya M; Yoshioka T; Ogasawara A; Hino R; Kojima R; Ueo H; Urano Y
ACS Cent Sci; 2020 Dec; 6(12):2217-2227. PubMed ID: 33376783
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of α-l-fucosidase 1 suppresses glioma progression by enhancing autophagy and inhibiting macrophage infiltration.
Xu L; Li Z; Song S; Chen Q; Mo L; Wang C; Fan W; Yan Y; Tong X; Yan H
Cancer Sci; 2020 Jul; 111(7):2284-2296. PubMed ID: 32314457
[TBL] [Abstract][Full Text] [Related]
19. High FUT3 expression is a marker of lower overall survival of breast cancer patients.
do Nascimento JCF; Beltrão EIC; Rocha CRC
Glycoconj J; 2020 Apr; 37(2):263-275. PubMed ID: 32062822
[TBL] [Abstract][Full Text] [Related]
20. Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma.
Yu X; Zhang R; Yang T; Zhang M; Xi K; Lin Y; Wen Y; Wang G; Huang Z; Zhang X; Zhang L
J Thorac Dis; 2019 Sep; 11(9):3980-3990. PubMed ID: 31656672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
